Fig. 6: Exosomal miR-1 levels in biological fluids from dogs with mammary carcinoma and human breast cancer patients. | Experimental & Molecular Medicine

Fig. 6: Exosomal miR-1 levels in biological fluids from dogs with mammary carcinoma and human breast cancer patients.

From: Extracellular vesicle-mediated transfer of miRNA-1 from primary tumors represses the growth of distant metastases

Fig. 6

a Schematic diagram of exosomes derived from human breast cancer patients and subjects with canine mammary carcinoma. b NTA was used to analyze the size of the exosomes. Size distribution of human serum-derived exosomes (left) and dog plasma-derived exosomes (right). c TEM image showing the external appearance of the exosomes. Top: human serum-derived exosomes. Bottom: dog plasma-derived exosomes. d The levels of miR-1 in the exosomes of dogs with canine mammary carcinoma (n = 7) and healthy controls (n = 6) were examined using qRT‒PCR and normalized to the Uni 6 spike-in as a control. e Expression levels of miR-1 in human breast cancer patients (n = 31) and healthy controls (n = 9) were examined using qRT‒PCR and normalized to the Uni 6 spike-in as the control. miR-1 was greater in breast cancer patients than in healthy controls, especially in late-stage (TNM stage III) patients compared to healthy controls. (stage 0: n = 9, stage I: n = 9, stage II: n = 9, stage III: n = 4) *P < 0.05, **P < 0.01, ***P < 0.001. f In silico Kaplan‒Meier analysis of breast cancer patients (http://kmplot.com/analysis/). OS curve comparing patients with high (red) and low (black) miRNA-1 expression. miR-1 (top) and HACE1 (bottom) expression in breast cancer patients with or without lymph node metastasis. Left: analysis of all patients. Middle: analysis of lymph node-negative patients. Right: analysis of lymph node-positive patients. Figure 6a was created with BioRender.com.

Back to article page